Brief: Scpharmaceuticals Inc Says Furoscix New Drug Application Resubmission Anticipated In Q3 2021

Scpharmaceuticals

23/03/2021 11:30

March 23 (Reuters) - scPharmaceuticals Inc  SCPH.O :
    * . REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL
RESULTS
AND PROVIDES BUSINESS UPDATE
    * FUROSCIX® NEW DRUG APPLICATION RESUBMISSION ANTICIPATED IN
Q3
2021
    * FREEDOM CLINICAL STUDY ON TRACK FOR TOPLINE RESULTS IN Q3
2021
    * QTRLY LOSS PER SHARE $0.28
    * Q4 EARNINGS PER SHARE VIEW $-0.36 -- REFINITIV IBES DATA
    * FORECASTS ITS 2021 NET LOSS TO BE $32 TO $36 MILLION.

Source text for Eikon:  ID:nGNX1kLtr9 
Further company coverage:  SCPH.O 

 ((Reuters.Briefs@thomsonreuters.com;))